US-based ImaCor has introduced its all-in-one platform for advanced hemodynamic management, which includes hTEE, hTTE and Zura ultrasound systems.


According to the company, hTEE is enabled by the ClariTEE probe that can be left indwelling for 72 hours and hTTE is a transthoracic probe for complementary hemodynamic management.

Zura ultrasound systems, including the Zura EVO-1, offers new advanced processing for better imaging, said ImaCor.

ImaCor president and CEO Peter Pellerito said: "Strategically, our all-in-one hemodynamic management platform fulfills our vision of providing the most advanced technology in critical care.

"The new system delivers a higher level of capabilities to our customers, avoiding dramatic cost, while saving time, money, and ultimately, lives."

The platform is said to display cardiac filling, as well as provides heomodynamic trending and function data over time in a dashboard format and sizeable image quality improvements with 7mHz resolution at 18cm depth.

Thomas Jefferson University Hospital surgical critical care unit director Nicholas Cavarocchi said: "I am impressed with the significant image quality improvements on ImaCor’s all-in-one hemodynamic management platform – it provides the whole picture in critical care."

The company has received 510(k) approval from the US Food and Drug Administration for its transthoracic echocardiography (TTE) probe, making its platform the first-of-its-kind for hemodynamic management.

Image: ImaCor all-in-one hemodynamic management platform with hTEE technology enabled by a ClariTEE probe and 510(K) cleared hTTE probe. Photo: courtesy of Business Wire.